Scroll

cefoxitin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	550	35607-66-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefoxitin cefoxitin sodium cephoxitin cefoxitin sodium salt	A semisynthetic cephamycin antibiotic resistant to beta-lactamase. Molecular weight: 427.45 Formula: C16H17N3O7S2 CLOGP: -0.32 LIPINSKI: 0 HAC: 10 HDO: 3 TPSA: 148.26 ALOGS: -3.34 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefoxitin
cefoxitin sodium
cephoxitin
cefoxitin sodium salt

A semisynthetic cephamycin antibiotic resistant to beta-lactamase.

Molecular weight: 427.45
Formula: C16H17N3O7S2
CLOGP: -0.32
LIPINSKI: 0
HAC: 10
HDO: 3
TPSA: 148.26
ALOGS: -3.34
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
6	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	85 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	401.04 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance)	3.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1000 mg/mL	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	0.81 hours	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.73 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.17 L/kg	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Oct. 18, 1978	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	127.91	31.75	40	1125	33796	63454061
Systemic mastocytosis	111.33	31.75	15	1150	166	63487691
Drug resistance	61.72	31.75	21	1144	22912	63464945
Catatonia	47.95	31.75	12	1153	4465	63483392
Pathogen resistance	39.11	31.75	11	1154	6387	63481470
Rash maculo-papular	37.62	31.75	16	1149	31880	63455977
Anaphylactic reaction	31.89	31.75	18	1147	66082	63421775

Showing 1 to 7 of 7 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	76.23	39.87	29	823	32983	34923096
Drug resistance	53.45	39.87	21	831	25906	34930173
Treatment failure	41.59	39.87	21	831	46676	34909403
Mycobacterium chelonae infection	40.04	39.87	8	844	807	34955272

Showing 1 to 4 of 4 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	188.54	28.93	68	1952	64176	79678192
Systemic mastocytosis	97.14	28.93	15	2005	322	79742046
Rash maculo-papular	69.32	28.93	32	1988	56046	79686322
Drug resistance	61.42	28.93	27	1993	42186	79700182
Ototoxicity	52.84	28.93	13	2007	3261	79739107
Anaphylactic shock	49.06	28.93	22	1998	35974	79706394
Pathogen resistance	48.81	28.93	17	2003	14325	79728043
Thrombocytopenia	42.00	28.93	42	1978	265217	79477151
Catatonia	36.15	28.93	12	2008	8744	79733624
Mycobacterium chelonae infection	35.85	28.93	9	2011	2447	79739921

Showing 1 to 10 of 14 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J01DC01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Second-generation cephalosporins
CHEBI has role	CHEBI:36047	antibacterial drugs
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Showing 1 to 6 of 6 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Gonorrhea	indication	15628003	DOID:7551
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Staphylococcal pneumonia	indication	22754005
Streptococcal septicemia	indication	29577008
Postoperative infection	indication	33910007
Pneumonia due to Streptococcus	indication	34020007
Peritonitis	indication	48661000

Showing 1 to 10 of 87 entries

Previous1 2 3 4 5…9Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.54	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme	PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR			CHEMBL	CHEMBL
Beta-lactamase	Enzyme	BLAC_BACLI				WOMBAT-PK
Beta-lactamase	Enzyme	A2RP81_CITFR		Ki	6.85	CHEMBL
Penicillin-binding protein 1A	Enzyme	PBPA_CLOPE				WOMBAT-PK
Beta-lactamase	Enzyme	D6NSM8_ACIBA		Ki	6.30	CHEMBL
Streptokinase A	Enzyme	STRP_STRP1		EC50	5.48	WOMBAT-PK
Beta-lactamase	Enzyme	B2ZTR6_ACIBA		Ki	7	CHEMBL

Showing 1 to 7 of 7 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
CFX	PDB_CHEM_ID
002722	NDDF
004843	NDDF
10937	IUPHAR_LIGAND_ID
203118	RXNORM
33155	MMSL
33564-30-6	SECONDARY_CAS_RN
3397	INN_ID
372780005	SNOMEDCT_US
37872	MMSL

Showing 1 to 10 of 28 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefoxitin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9876	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	27 sections
Cefoxitin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9876	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	27 sections
Cefoxitin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9877	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	26 sections
Cefoxitin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9877	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	26 sections
Cefoxitin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9878	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Cefoxitin	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9878	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Cefoxitin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-109	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	25 sections
Cefoxitin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-110	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	25 sections
Cefoxitin	HUMAN PRESCRIPTION DRUG LABEL	1	25021-111	INJECTION, POWDER, FOR SOLUTION	10 g	INTRAVENOUS	ANDA	27 sections
Cefoxitin	HUMAN PRESCRIPTION DRUG LABEL	1	44567-245	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	23 sections

Showing 1 to 10 of 29 entries

Previous1 2 3Next